JP MORGAN/CALL/BECTON DICKINSON AND CO./295/0.1/17.01.25 Stock

Warrant

DE000JL0BUH6

Real-time Bid/Ask 07:12:37 2024-05-22 EDT
0.47 EUR / 0.67 EUR +5.56% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./295/0.1/17.01.25
Current month-15.62%
1 month-19.40%
Date Price Change
24-05-22 0.48 -11.11%
24-05-21 0.54 -1.82%
24-05-20 0.55 +1.85%
24-05-17 0.54 -11.48%
24-05-16 0.61 +8.93%

Delayed Quote Börse Stuttgart

Last update May 22, 2024 at 03:44 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL0BUH
ISINDE000JL0BUH6
Date issued 2023-04-13
Strike 295 $
Maturity 2025-01-17 (241 Days)
Parity 10 : 1
Emission price 2
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.53
Lowest since issue 0.48
Spread 0.2
Spread %29.41%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
234.9 USD
Average target price
279 USD
Spread / Average Target
+18.79%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW